$AMIX News

Last published 15h ago

15h agoAMIXAutonomix Highlights Renal Denervation Strategy and Vision for Illuminating the Nervous System at TCT 2026GlobeNewswireMicrochip-enabled sensing platform aims to combine signal acquisition, mapping and real-time catheter positioning to support future nerve-targeted procedures
2d agoAMIXAutonomix Medical Granted New U.S. Patent Strengthening Proprietary Catheter-Based Sensing TechnologyGlobeNewswireLatest patent expands intellectual property protection for advanced physiological signal acquisition and processing
1mo agoAMIXAutonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of DirectorsGlobeNewswireAppointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervation and other category-defining technologies THE WOODLANDS,
2mo agoAMIXAutonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026GlobeNewswireAbstracts highlight potential of Autonomix’s transvascular technology across pain management and nervous system mapping THE WOODLANDS, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX)
2mo agoAMIXAutonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy DeliveryGlobeNewswireNew patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pain THE WOODLANDS,
2mo agoAMIXAutonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq RulesGlobeNewswireTHE WOODLANDS, TX, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted
3mo agoAMIXAutonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA SubmissionGlobeNewswireFinal histology and laboratory analyses support the study’s safety and performance objectives THE WOODLANDS, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the
3mo agoAMIXAutonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement AwardGlobeNewswireRecognition honors one of the medical technology industry's most influential innovators, whose career has helped shape modern cardiovascular care THE WOODLANDS, TX, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Autonomix
3mo agoAMIXAutonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted TherapyGlobeNewswirePatent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain Strengthens Autonomix’s platform opportunity across oncology, autonomic
3mo agoAMIXAutonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical StudyGlobeNewswireData demonstrate the ability to detect, localize and confirm changes in renal neural activity, supporting continued development of physiology-guided renal denervation THE WOODLANDS, TX, July 24, 2026 (GLOBE NEWSWIRE)
3mo agoAMIXAutonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation PlatformGlobeNewswirePatent Broadens Intellectual Property Protecting Advanced Autonomic Nervous System Assessment Technologies Designed to Enhance Patient Selection, Treatment Precision and Future Clinical Applications THE WOODLANDS, TX,
4mo agoAMIXAutonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment PlatformGlobeNewswireNewly Issued Patent Expands Company's Neural Sensing Technology Platform into Large Urology Market Affecting Approximately 37 Million Americans THE WOODLANDS, TX, July 15, 2026 (GLOBE NEWSWIRE) -- Autonomix
4mo agoAMIXAutonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq RulesGlobeNewswireTHE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted
4mo agoAMIXAutonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent GrantGlobeNewswireIP portfolio reflects Autonomix’s neural sensing leadership in multi-billion-dollar denervation market Technical highlights on newly issued patent include real-time nerve monitoring and diagnostic evaluation THE
4mo agoAMIXAutonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity ChangeGlobeNewswirePlatform Expected to Target Expansion into Multi-Billion-Dollar Cardiovascular Market with Potential Class II Diagnostic Regulatory Path Architecture Supports Future Expansion into Denervation, including Renal,
4mo agoAMIXAutonomix Announces Reverse Stock SplitGlobeNewswireTHE WOODLANDS, TX, June 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today
5mo agoAMIXAutonomix Medical Announces Release of New CEO Corner Segment Highlighting Global Scientific and Clinical Recognition of Platform TechnologyGlobeNewswireAccess the segment here THE WOODLANDS, TX, June 10, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision
5mo agoAMIXAutonomix Medical Highlights Clinical Data Presented at Society of Surgical Oncology Annual Meeting in Virtual Investor "What This Means" Segment Featuring City of Hope Chief of MedicineGlobeNewswireDr. Toufic Kachaamy Discusses Visceral Cancer Pain Treatment Differentiation, Pancreatic Cancer Feasibility Data, and Peripheral Nervous System Platform Potential Access the segment here THE WOODLANDS, TX, June 04,
5mo agoAMIXAutonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural ValidationGlobeNewswireTechnology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall Patent strengthens intellectual property foundation for next-generation neuromodulation
5mo agoAMIXAutonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain MitigationGlobeNewswireTHE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today
6mo agoAMIXAutonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain MitigationGlobeNewswireTHE WOODLANDS, TX, April 29, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today
6mo agoAMIXAutonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026GlobeNewswireTHE WOODLANDS, TX, April 22, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today
7mo agoAMIXAutonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026GlobeNewswireTHE WOODLANDS, TX, April 08, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today
8mo agoAMIXAutonomix Medical Selected for Best Innovation Competition at CRT 2026GlobeNewswireTHE WOODLANDS, TX, March 05, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today
8mo agoAMIXAutonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve NeurolysisGlobeNewswireTHE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today
8mo agoAMIXAutonomix Medical Announces Release of New CEO Corner Segment Highlighting Publication Strategy and Scientific ValidationGlobeNewswireCEO, Brad Hauser, discusses building clinical credibility through rigorous science and peer-reviewed engagement THE WOODLANDS, TX, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix"
8mo agoAMIXAutonomix Medical Selected to Present New Long-Term Pain Mitigation Data in Pancreatic Cancer at SSO 2026 Annual Meeting in Podium PresentationGlobeNewswireTHE WOODLANDS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today
9mo agoAMIXAutonomix Medical to Present Final Analysis on Pain Mitigation in Pancreatic Cancer at SIO 2026 Annual Scientific MeetingGlobeNewswireTHE WOODLANDS, TX, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today
10mo agoAMIXAutonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers SymposiumGlobeNewswireNew subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage patients with otherwise limited treatment options THE WOODLANDS, TX, Jan.
10mo agoAMIXAutonomix Medical, Inc. Granted European Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in CardiologyGlobeNewswireWith over 80 issued patents and 39 pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation Newly granted patent further strengthens the Company's strategic
10mo agoAMIXAutonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect SegmentGlobeNewswireAccess the segment here THE WOODLANDS, TX, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision
10mo agoAMIXAutonomix Medical, Inc. Announces Abstract Selected for Poster Presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers SymposiumGlobeNewswireTHE WOODLANDS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today
11mo agoAMIXAutonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic GrowthGlobeNewswireTHE WOODLANDS, TX, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today
11mo agoAMIXAutonomix Medical, Inc. Announces Pricing of $5.0 Million Private Placement Priced At The Market Under Nasdaq RulesGlobeNewswireTHE WOODLANDS, TX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today
12mo agoAMIXAutonomix Medical, Inc. Reports Positive Subgroup Results Demonstrating Sustained Improvements in Quality of Life from Post Hoc Analysis of Pancreatic Cancer PoC StudyGlobeNewswireEORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and metastasis status, complementing previously reported pain reduction and opioid-free outcomes Late-stage
1y agoAMIXAutonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific ConferenceGlobeNewswireTHE WOODLANDS, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today
1y agoAMIXAutonomix Medical, Inc. to Highlight Innovative Nerve-Sensing and Ablation Platform at the 2025 Maxim Growth SummitGlobeNewswireTHE WOODLANDS, TX, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today
1y agoAMIXAutonomix Medical, Inc. Granted U.S. Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in CardiologyGlobeNewswireWith over 120 issued and pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation Newly issued patent strengthens the Company's strategic position in a
1y agoAMIXAutonomix Medical, Inc. Announces Release of the Next CEO Corner SegmentGlobeNewswireTHE WOODLANDS, TX, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today
1y agoAMIXAutonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2025 CIRSE Annual CongressGlobeNewswirePresentation to highlight findings from the first phase of the Company's ongoing first-in-human proof-of-concept (PoC) clinical trial THE WOODLANDS, TX, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical,
1y agoAMIXAutonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor "What This Means" SegmentGlobeNewswireDr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses the Company's recently announced results from the post hoc analysis of its proof-of-concept human clinical trial ("PoC 1") THE WOODLANDS, TX, Sept. 04,
1y agoAMIXAutonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 StudyGlobeNewswireNew longer-term post hoc analysis results of responders (n=6)1 showed long-lasting, durable pain reduction of nearly 66%, or a mean 5.08 reduction on the VAS pain scale, in patients with severe pancreatic cancer pain
1y agoAMIXAutonomix Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireTHE WOODLANDS, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how
1y agoAMIXAutonomix Medical, Inc. Granted New European Patent for First-in-Class Catheter-Based TechnologyGlobeNewswireGlobal patent estate encompasses 80 issued patents and 40 pending patent applications Strengthens strategic position in a multi-billion-dollar market opportunity across cardiovascular, renal, and other high-burden
1y agoAMIXAutonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc.GlobeNewswireLive video webcast on Thursday, August 21st at 1:00 PM ET Register here THE WOODLANDS, TX, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device
1y agoAIM AKTX AMIX CNSP+5JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025ACCESS NewswireRegister for the three-day event here FRENCHTOWN, NJ / ACCESS Newswire / August 15, 2025 / JTC Team , a fully integrated corporate communications and investor relations firm, today announced its
1y agoAMIXAutonomix Medical, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechGlobeNewswire– Live video webcast on Thursday, August 21st at 2:20 PM ET THE WOODLANDS, TX, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused
1y agoAMIXAutonomix Medical, Inc. Finalizes Design Review of First-Ever Intravascular Nerve Sensing Catheter in Key Step Toward U.S. Clinical StudiesGlobeNewswireMicrochip-based platform enables real-time nerve mapping and targeted treatment from within the vascular system Continued progress toward submitting Investigational Device Exemption ("IDE"), and if approved, the
1y agoAMIXAutonomix Medical, Inc. Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand ConferenceGlobeNewswire– Video webcast now available on-demand THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing
1y agoAMIXAutonomix Medical, Inc. Exercise of Warrants for $2.5 Million Gross ProceedsGlobeNewswireTHE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today